On 30th October, the "Award Ceremony for Grand Neo Bay 2023 - Top 10 Innovative and Entrepreneurial Enterprise" was held at the Grand Neo Bay Science and Innovation Building, hosted by the Minhang District Human Resources and Social Security Bureau. The event aims to further develop a functional support platform for high-quality innovation and entrepreneurship in the southern part of Shanghai, accelerate the construction of the "Grand Neo Bay" area, cultivate a large number of high-tech, high-quality and high-growth future unicorn enterprises for Minhang and even for Shanghai, and support Shanghai become a world-leading science and technology innovation centre.
LWBP was awarded "Grand Neo Bay 2023 - Top 10 Innovative and Entrepreneurial Enterprise - Biomedical Sector". This honour is not only an affirmation of our company's long-term persistence in innovation, but also a high recognition of our company's commitment to independently developing world-competitive innovative drugs.
Since founded, LWBP has been committed to the principle of "Innovation and Excellence", and is dedicated to independently developing world-leading innovative pharmaceutical products with global intellectual property rights to meet the unmet clinical needs. Focusing on novel drug development and industrialization in the areas of antiviral, oncology and autoimmune diseases, LWBP has carried out a number of independently developed small molecule innovative drug projects (first in class), and a number of products have entered the clinical trial stage, of which two clinical studies have entered Phase 2 stage. The clinical evaluation indexes of our core products have reached the international leading level, which is expected to become a major breakthrough in the related field (best in class).
Driven by independent innovation and R&D, LWBP is committed to becoming a global leading-level small molecule drug R&D enterprise by constructing a globally competitive product pipeline and rapidly advancing the clinical research and industrialization process of our core products. At present, LWBP has applied for more than 70 invention patents, and more than 40 patents have been authorized, with authorization covering more than 20 countries in Asia-Pacific, North America, Europe, etc. These patents have high commercial value and industrialization prospects, and enable the company to have the competitive ability to participate in the global drug innovation research and development. With a focus on meeting unmet clinical needs, driven by independent intellectual property rights, and with a team of professional talents, LWBP is committed to building a global leading company in the R&D and industrialization of innovative medicines.
